ImmunoMet is a clinical stage oncology company with a best in class mechanism and genuinely strong data. Their old website and pitch deck made them look like everyone else. We rebuilt both around one idea: the science is the story. A BIO International deck built to be presented, and a cinematic website to greet the investors it warms up.
The old corporate deck had all the substance: the mechanism, the MD Anderson trial, the platform. But every slide wore the same blue header and the same wall of text, so the best-in-class story read like a filing, not a pitch.
Real slides from the original corporate deck. All the facts, none of the story.
No template, no reskin. The same process we bring to every founder: sharpen the message, rebuild the deck around it, then carry the same story to the web. The rest of this page is those three moves, in order.
We started with the story, not the software. One idea survived every pass: the science is the story. Every headline was rewritten so a best in class mechanism reads like one in seconds, without a walkthrough.
Sixteen slides rebuilt from the template up: one idea per slide, data given room, the argument in the order investors buy it. Built to be presented at BIO International, not read like a filing.
The same system became the website. The investor who meets the deck in San Diego and Googles the company that night lands on the same story, the same confidence.
The old deck was written in topics: Summary of Opportunity, Unmet Medical Need. Topics make the investor do the work. We rewrote the headlines so every slide states its point before the eye reaches the body.
"Summary of Opportunity", then seven bullets the reader has to mine for the point.
The case in five key points. Mechanism, proof, indication, platform, believers, in the order investors buy it.
"GBM Overview, Unmet Medical Need", with the actual gap sitting mid-page in a wall of bullets.
GBM: 20 years without a new standard of care. The gap is the first thing the room reads.
Here are the real slides, before and after. Same science, same facts, rebuilt in the brand so each slide carries one idea an investor can hold.
The cover. From a template title page to a BIO International opener that looks like the science it carries.
The unmet need. A wall of bullets becomes one hard fact: 20 years without a new standard of care.
The clinical development plan. A crowded flowchart becomes a plan an investor can follow in one pass.
At BIO International in San Diego, the rebuilt deck did its job live. Open on the gap, land the mechanism, prove it with the trial, then make the ask. Sixteen slides, every one earning the next.
A single palette and type system, so the company looks like itself everywhere an investor meets it.
The old site was a 2018 template that buried the story. Here it is, beside the site today, exactly as it lives at immunomet.com.
Science Clinical Pipeline Investors Team About Contact Us
ImmunoMet Therapeutics is a clinical-stage oncology company developing lixumistat (IM156), a best-in-class OxPhos inhibitor that targets the metabolic dependency driving cancer-cell survival in resistant tumours.
The old site beside the site today. Scroll inside the old frame.
If your science is ahead of your slides, that is the gap we close. Website, investor deck, or both.